Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a causative agent of the pandemic coronavirus disease 2019 (COVID-19), which has resulted in over two million deaths worldwide to date. Diphyllin and diphyllinosides are known as natural blockers of cellular vacuolar ATPases, and so can act as inhibitors of the pH-dependent fusion of viral envelopes with host cell endosomal membranes. Such pH-dependent fusion is a critical early step during the SARS-CoV-2 replication cycle. Accordingly, the anti-SARS-CoV-2 profiles and cytotoxicities of diphyllin, diphyllinoside cleistanthin B, and two structurally related compounds, helioxanthin 8-1 and helioxanthin 5-4-2, are evaluated here using in vitro cell-based assay systems. Neither helioxanthin exhibits any obvious anti-SARS-CoV-2 effects in vitro. By contrast diphyllin and cleistanthin B do exhibit anti-SARS-CoV-2 effects in Vero cells, with respective 50% effective concentrations (EC50) values of 1.92 and 6.51 µM. Diphyllin displays anti-SARS-CoV-2 effect also in colorectal adenocarcinoma (CaCo-2) cells. Moreover, when diphyllin is added at various times post infection, a significant decrease in viral titer is observed in SARS-CoV-2-infected Vero cells, even at high viral multiplicities of infection. Importantly, neither diphyllin nor cleistanthin B are found cytotoxic to Vero cells in concentrations up to 100 µM. However, the cytotoxic effect of diphyllin is more pronounced in Vero E6 and CaCo-2 cells. Overall, our data demonstrate that diphyllin and diphyllin analogues might be perfected as anti-SARS-CoV-2 agents in future preclinical studies, most especially if nanomedicine approaches may be invoked to optimize functional drug delivery to virus infected cells.

Department of Chemistry and Biochemistry Mendel University in Brno CZ 61300 Brno Czech Republic

Department of Virology Veterinary Research Institute CZ 62100 Brno Czech Republic

Institute of Parasitology Biology Centre of the Czech Academy of Sciences CZ 37005 Ceske Budejovice Czech Republic

KP Therapeutics s r o CZ 61200 Brno Czech Republic

Zobrazit více v PubMed

Tu Y.F., Chien C.S., Yarmishyn A.A., Lin Y.Y., Luo Y.H., Lin Y.T., Lai W.Y., Yang D.M., Chou S.J., Yang Y.P., et al. A Review of SARS-CoV-2 and the Ongoing Clinical Trials. Int. J. Mol. Sci. 2020;21:2657. doi: 10.3390/ijms21072657. PubMed DOI PMC

Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5. PubMed DOI PMC

Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X., Liu L., Shan H., Lei C.L., Hui D.S.C., et al. China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 2020;382:1708–1720. doi: 10.1056/NEJMoa2002032. PubMed DOI PMC

Paraskevis D., Kostaki E.G., Magiorkinis G., Panayiotakopoulos G., Sourvinos G., Tsiodras S. Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. Infect. Genet. Evol. 2020;79:104212. doi: 10.1016/j.meegid.2020.104212. PubMed DOI PMC

Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., Wang B., Xiang H., Cheng Z., Xiong Y., et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323:1061–1069. doi: 10.1001/jama.2020.1585. PubMed DOI PMC

Martinez-Lopez A., Persaud M., Chavez M.P., Zhang H., Rong L., Liu S., Wang T.T., Sarafianos S.G., Diaz-Griffero F. Glycosylated diphyllin as a broad-spectrum antiviral agent against Zika virus. EBioMedicine. 2019;47:269–283. doi: 10.1016/j.ebiom.2019.08.060. PubMed DOI PMC

Hu C.J., Chang W.S., Fang Z.S., Chen Y.T., Wang W.L., Tsai H.H., Chueh L.L., Takano T., Hohdatsu T., Chen H.W. Nanoparticulate vacuolar ATPase blocker exhibits potent host-targeted antiviral activity against feline coronavirus. Sci. Rep. 2017;7:13043. doi: 10.1038/s41598-017-13316-0. PubMed DOI PMC

Cui Q., Du R., Liu M., Rong L. Lignans and Their Derivatives from Plants as Antivirals. Molecules. 2020;25:183. doi: 10.3390/molecules25010183. PubMed DOI PMC

Sørensen M.G., Henriksen K., Neutzsky-Wulff A.V., Dziegiel M.H., Karsdal M.A. Diphyllin, a novel and naturally potent V-ATPase inhibitor, abrogates acidification of the osteoclastic resorption lacunae and bone resorption. J. Bone Miner. Res. 2007;22:1640–1648. doi: 10.1359/jbmr.070613. PubMed DOI

Shen W., Zou X., Chen M., Liu P., Shen Y., Huang S., Guo H., Zhang L. Effects of diphyllin as a novel V-ATPase inhibitor on gastric adenocarcinoma. Eur. J. Pharmacol. 2011;667:330–338. doi: 10.1016/j.ejphar.2011.05.042. PubMed DOI

Rocha M.P., Campana P.R.V., Scoaris D.O., Almeida V.L., Lopes J.C.D., Shaw J.M.H., Silva C.G. Combined In Vitro Studies and in Silico Target Fishing for the Evaluation of the Biological Activities of Diphylleia cymosa and Podophyllum hexandrum. Molecules. 2018;23:3303. doi: 10.3390/molecules23123303. PubMed DOI PMC

Di Giorgio C., Delmas F., Akhmedjanova V., Ollivier E., Bessonova I., Riad E., Timon-David P. In vitro antileishmanial activity of diphyllin isolated from Haplophyllum bucharicum. Planta Med. 2005;71:366–369. doi: 10.1055/s-2005-864106. PubMed DOI

Chen H.W., Cheng J.X., Liu M.T., King K., Peng J.Y., Zhang X.Q., Wang C.H., Shresta S., Schooley R.T., Liu Y.T. Inhibitory and combinatorial effect of diphyllin, a v-ATPase blocker, on influenza viruses. Antivir. Res. 2013;99:371–382. doi: 10.1016/j.antiviral.2013.06.014. PubMed DOI PMC

Zhang H.J., Rumschlag-Booms E., Guan Y.F., Liu K.L., Wang D.Y., Li W.F., Nguyen V.H., Cuong N.M., Soejarto D.D., Fong H.H.S., et al. Anti-HIV diphyllin glycosides from Justicia gendarussa. Phytochemistry. 2017;136:94–100. doi: 10.1016/j.phytochem.2017.01.005. PubMed DOI

Asano J., Chiba K., Tada M., Yoshii T. Antiviral activity of lignans and their glycosides from Justicia procumbens. Phytochemistry. 1996;42:713–717. doi: 10.1016/0031-9422(96)00024-6. PubMed DOI

Yeo H., Li Y., Fu L., Zhu J.L., Gullen E.A., Dutschman G.E., Lee Y., Chung R., Huang E.S., Austin D.J., et al. Synthesis and antiviral activity of helioxanthin analogues. J. Med. Chem. 2005;48:534–546. doi: 10.1021/jm034265a. PubMed DOI

Zhang H.J., Rumschlag-Booms E., Guan Y.F., Wang D.Y., Liu K.L., Li W.F., Nguyen V.H., Cuong N.M., Soejarto D.D., Fong H.H.S., et al. Potent Inhibitor of Drug-Resistant HIV-1 Strains Identified from the Medicinal Plant Justicia gendarussa. J. Nat. Prod. 2017;80:1798–1807. doi: 10.1021/acs.jnatprod.7b00004. PubMed DOI

Li Y., Fu L., Yeo H., Zhu J.L., Chou C.K., Kou Y.H., Yeh S.F., Gullen E., Austin D., Cheng Y.C. Inhibition of hepatitis B virus gene expression and replication by helioxanthin and its derivative. Antivir. Chem. Chemother. 2005;16:193–201. doi: 10.1177/095632020501600305. PubMed DOI

Ying C., Tan S., Cheng Y.C. Helioxanthin analogue 8-1 inhibits duck hepatitis B virus replication in cell culture. Antivir. Chem. Chemother. 2010;21:97–103. doi: 10.3851/IMP1686. PubMed DOI

De Madrid A.T., Porterfield J.S. A simple micro-culture method for the study of group B arboviruses. Bull. World Health Organ. 1969;40:113–121. PubMed PMC

Eyer L., Valdés J.J., Gil V.A., Nencka R., Hřebabecký H., Šála M., Salát J., Černý J., Palus M., De Clercq E., et al. Nucleoside inhibitors of tick-borne encephalitis virus. Antimicrob. Agents Chemother. 2015;59:5483–5493. doi: 10.1128/AAC.00807-15. PubMed DOI PMC

Nanoformulation of the Broad-Spectrum Hydrophobic Antiviral Vacuolar ATPase Inhibitor Diphyllin in Human Recombinant H-ferritin

Antiviral activity of singlet oxygen-photogenerating perylene compounds against SARS-CoV-2: Interaction with the viral envelope and photodynamic virion inactivation

Collective behavior of magnetic microrobots through immuno-sandwich assay: On-the-fly COVID-19 sensing

Diphyllin Shows a Broad-Spectrum Antiviral Activity against Multiple Medically Important Enveloped RNA and DNA Viruses